Testing to Target in Non-Small Cell Lung Cancer: Managed Care Perspectives
Recent advancements in the scientific knowledge of non-small cell lung cancer (NSCLC) pathology have shifted the paradigm of care from a “one-size fits all” regimen, to one that focuses on individualized therapy and integrating biomarker-targeted therapies into treatment paradigms. The number of approved and emerging NSCLC targeted therapies tops a dozen. These new cancer agents contribute substantially to improved outcomes for patients as well as rising healthcare costs. Experts indicate that the key to providing cost-effective care is to better match patients with specifically targeted treatment options.
This live webcast will highlight the latest clinical evidence about the role of genetic and molecular targets in developing personalized treatment plans for patients with NSCLC, with a special focus on opportunities for managed care and specialty pharmacists to facilitate individualized care. Expert faculty will offer insights on evolving best practices for biomarker testing and interpretation to optimize therapy choice, recent data from the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, and the pharmacoeconomic implications of biomarker-directed NSCLC management.
This activity is designed for managed care and specialty pharmacists. No prerequisites required.
The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. Upon the conclusion of this activity, the participant should be able to:
- ASSESS the role of genetic and molecular biomarkers in guiding NSCLC treatment plans.
- EVALUATE the safety, efficacy, and therapeutic role of new and emerging targeted therapies.
- RECOMMEND pharmacy-driven strategies to facilitate individualized NSCLC management.
R. Donald Harvey, PharmD, FCCP, BCOP (Course Director)
Associate Professor, Hematology/Medical Oncology
Director, Phase I Clinical Trials Section
Winship Cancer Institute of Emory University
Matthew Farber, MA
Oncology Disease State
Walgreens Specialty Pharmacy
- 1.50 ACPE